Trials / Completed
CompletedNCT01935154
Efficacy Study of Vx001 Vaccine in NSCLC Patients
Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 221 (actual)
- Sponsor
- Vaxon Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A\*0201 positive patients with TERT expressing tumors will be included. The objective of the trial is survival rate at 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vx-001 | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
- First posted
- 2013-09-04
- Last updated
- 2019-06-19
Locations
70 sites across 8 countries: Czechia, France, Germany, Greece, Italy, Poland, Romania, Spain
Source: ClinicalTrials.gov record NCT01935154. Inclusion in this directory is not an endorsement.